Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains

Folia Microbiologica

Volumn 59, Issue 3, 2014, Pages 209-215

  Beran, Vladimir ^a   Chmelar, Dittmar ^a   Vobejdova, Jana ^b   Konigova, Adela ^a   Nemec, Jakub ^a   Tvrdik, Josef ^a  

^a UNIVERSITY OF OSTRAVA   (Czech Republic)

^b Litomysl's Hospital   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL TOXIN;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; CROSS INFECTION; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 84897431724     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12223-013-0283-1     Document Type: Article

References (41)

1. Akerlund T, Svenungsson B, Lagergren A, Burman LG (2006) Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 44: 353-358. doi: 10. 1128/JCM. 44. 2. 353-358. 2006.
2. Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH (2009) Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 63: 520-525. doi: 10. 1093/jac/dkn502.
3. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346: 334-339. doi: 10. 1056/NEJMcp011603.
4. Bligny D, Cador B, Jolivet-Gougeon A, Le Strat A, Cazalets C, Laurat E, Jego P, Bouget J, Grosbois B (2002) Clostridium difficile infection in a Department of Internal Medicine. A consecutive series of 45 patients. Ann Med Interne 153: 291-299 (in French).
5. Boyanova L, Mitev A, Gergova G, Mateev G, Mitov I (2012) High prevalence and resistance rates to antibiotics in anaerobic bacteria in specimens from patients with chronic balanitis. Anaerobe 18: 414-416. doi: 10. 1016/j. anaerobe. 2012. 06. 002.
6. Butler MM, Shinabarger DL, Citron DM, Kelly C, Dvoskin S, Wright GE, Feng HP, Tzipori S, Bowlin TL (2012) MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother 56: 4786-4792. doi: 10. 1128/AAC. 00508-12.
7. Cattoir V, Ould-Hocine ZF, Legrand P (2008) Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital. Pathol Biol 56: 407-411. doi: 10. 1016/j. patbio. 2008. 07. 022 (in French).
8. Chilton CH, Freeman J, Crowther GS, Todhunter SL, Wilcox MH (2012) Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 67: 2434-2437. doi: 10. 1093/jac/dks243.
9. Citron DM, Babakhani F, Goldstein EJC, Nagaro K, Sambol S, Sears P, Shue YK, Gerding DN (2009) Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 15: 234-236. doi: 10. 1016/j. anaerobe. 2009. 09. 005.
10. Dubberke ER, Butler AM, Hota B, Khan YM, Mangino JE, Mayer J, Popovich KJ, Stevenson KB, Yokoe DS, McDonald LC, Jernigan J, Fraser VJ (2009) Multicenter study of the impact of community-onset Clostridium difficile infection on surveillance for C. difficile infection. Infect Control Hosp Epidemiol 30: 518-525. doi: 10. 1086/597380.
11. Dubberke ER, Haslam DB, Lanzas C, Bobo LD, Burnham CA, Grohn YT, Tarr PI (2010) The ecology and pathobiology of Clostridium difficille infections: an interdisciplinary challenge. Zoonoses Public Health 58: 4-20. doi: 10. 1111/j. 1863-2378. 2010. 01352. x.
12. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M (2009) Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis 48: 568-576. doi: 10. 1086/596703.
13. Hintze J (2001) NCSS and PASS, Number Cruncher Statistical Systems. Kaysville, Utah, USA. http://www. ncss. com/.
14. Huang HH, Weintraub A, Fang H, Wu S, Zhang YY, Nord CE (2010) Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 16: 633-635. doi: 10. 1016/j. anaerobe. 2010. 09. 002.
15. John R, Brazier JS (2005) Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 61: 11-14. doi: 10. 1016/j. jhin. 2005. 01. 020.
16. Kim J, Kang JO, Pai H, Choi TY (2012) Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Ag 40: 24-29. doi: 10. 1016/j. ijantimicag. 2012. 03. 015.
17. Kuijper EJ, van den Berg RJ, Brazier JS (2009) Comparison of molecular typing methods applied to Clostridium difficile. Methods Mol Biol 551: 159-171. doi: 10. 1007/978-1-60327-999-4_13.
18. McDonald LC, Owings M, Jernigan DB (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409-415.
19. Mutlu E, Wroe AJ, Sanchez-Hurtado K, Brazier JS, Poxton IR (2007) Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 56: 921-929. doi: 10. 1099/jmm. 0. 47176-0.
20. Noren T, Alriksson I, Akerlund T, Burman LG, Unemo M (2010) In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 16: 1104-1110. doi: 10. 1111/j. 1469-0691. 2009. 03048. x.
21. Norman KN, Harvey RB, Scott HM, Hume ME, Andrews K, Brawley AD (2009) Varied prevalence of Clostridium difficile in an integrated swine operation. Anaerobe 15: 256-260. doi: 10. 1016/j. anaerobe. 2009. 09. 006.
22. Nyc O, Pituch H, Matejkova J, Obuch-Woszczatynski P, Kuijper EJ (2011) Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. Lancet 377: 1407-1407. doi: 10. 1016/S0140-6736(11)60575-8.
23. O'Connor R, Baines SD, Freeman J, Wilcox MH (2008) In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother 62: 762-765. doi: 10. 1093/jac/dkn276.
24. O'Connor JR, Johnson S, Gerding DN (2009) Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924. doi: 10. 1053/j. gastro. 2009. 02. 073.
25. Pelaez T, Cercenado E, Alcala L, Marin M, Martin-Lopez A, Martinez-Alarcon J, Catalan P, Sanchez-Somolinos M, Bouza E (2008) Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 46: 3028-3032. doi: 10. 1128/JCM. 00524-08.
26. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41: 1254-1260. doi: 10. 1086/496986.
27. Pituch H, Obuch-Woszczatynski P, Wultanska D, Nurzynska G, Harmanus C, Banaszkiewicz A, Radzikowski A, Luczak M, van Belkum A, Kuijper E (2011) Characterization and antimicrobial susceptibility of Clostridium difficile strains isolated from adult patients with diarrhoea hospitalized in two university hospitals in Poland, 2004-2006. J Med Microbiol 60: 1200-1205. doi: 10. 1099/jmm. 0. 029801-0.
28. Reil M, Hensgens MPM, Kuijper EJ, Jakobiak T, Gruber H, Kist M, Borgmann S (2012) Seasonality of Clostridium difficile infections in southern Germany. Epidemiol Infect 140: 1787-1793. doi: 10. 1017/S0950268811002627.
29. Riddle DJ, Dubberke ER (2009) Trends in Clostridium difficile disease: epidemiology and intervention. Infect Med 26: 211-220.
30. Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SLJ (2001) Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 147: 439-447.
31. Rupnik M, Wilcox MH, Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7: 526-536. doi: 10. 1038/nrmicro2164.
32. Solomon K, Fanning S, McDermott S, Murray S, Scott L, Martin A, Skally M, Burns K, Kuijper E, Fitzpatrick F, Fenelon L, Kyne L (2011) PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates. J Antimicrob Chemother 66: 1976-1982. doi: 10. 1093/jac/dkr275.
33. Spigaglia P, Barbanti F, Mastrantonio P (2011) Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 66: 2227-2234. doi: 10. 1093/jac/dkr292.
34. Taori SK, Hall V, Poxton IR (2010) Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 59: 338-344. doi: 10. 1099/jmm. 0. 014829-0.
35. Tschudin-Sutter S, Widmer AF, Perl TM (2012) Clostridium difficile: novel insights on an incessantly challenging disease. Curr Opin Infect Dis 25: 405-411. doi: 10. 1097/QCO. 0b013e32835533a2.
36. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW (2012) Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol 61: 49-56. doi: 10. 1099/jmm. 0. 036194-0.
37. Vojtilova L, Freibergerova M, Jurankova J, Husa P, Polak P, Kocourkova H (2011) A study of patients with Clostridium difficile infection hospitalized at Brno Clinic of Infectious Diseases in 2007-2010. Klin Mikrobiol Infekc Lek 6: 208-213 (in Czech).
38. Von Eichel-Streiber C, Braun V (2008) Das difficile Clostridium/The difficile Clostridium. Lab Medizin 32: 219-234. doi: 10. 1515/JLM. 2008. 043 (in German).
39. Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tull P, Gastmeier P, van den Broek PJ, Colville A, Coignard B, Daha T, Debast S, Duerden BI, van den Hof S, van der Kooi T, Maarleveld HJH, Nagy E, Notermans DW, O'Driscoll J, Patel B, Stone S, Wiuff C (2008) Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 14: 2-20. doi: 10. 1111/j. 1469-0691. 2008. 01992. x.
40. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084. doi: 10. 1016/S0140-6736(05)67420-X.
41. Wiuff C, Brown DJ, Mather H, Banks A, Eastaway A, Coia JE (2011) The epidemiology of Clostridium difficile in Scotland. J Infect 62: 271-279. doi: 10. 1016/j. jinf. 2011. 01. 015.